logo
Joint Commission CEO Breaks Down New AI Certification

Joint Commission CEO Breaks Down New AI Certification

Newsweek26-06-2025
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
I've settled on my word of the week: transparency. Over the last seven days, my schedule has looked like a patchwork quilt, spanning several distinct sectors of the health care industry. But from the government's roundtable on prior authorization reform to my conversation with Joint Commission CEO Dr. Jonathan Perlin (read on for more on both of those), transparency has emerged as a common thread.
Health systems and insurance companies must be transparent with one another; health systems and insurance companies must be transparent with patients. And, of course, health care companies must be transparent with their employees and customers—especially when deploying AI.
Monday through Wednesday, many of my colleagues were in sunny Sonoma, California, for Newsweek's cross-industry AI Impact Summit. Senior Reporters Lauren Giella and Katherine Fung kept eyes on the health care side of the agenda, which included speakers from Kaiser Permanente, Hospital for Special Surgery, AdventHealth and UMass Medical.
"Transparency was a big theme for AI adoption in health care—not only when dealing with medical records and personal data, but also for why and how organizations are implementing automation tools," Giella wrote.
Dr. Allen Chang, ACMIO at UMass Medical, warned the audience not to neglect employees' concerns about losing jobs to AI, nodding to last year's strike by the California Nurses Association.
"A lot of us say that we're not going to be replaced by AI, we want to believe that, but in medicine, we can't just invoke this and expect that to address the underlying drivers as to why people are asking about this," Chang said on Tuesday's health care panel.
What could those underlying drivers be? I found some clues in Wolters Kluwer Health's new generative AI readiness report, released at the start of the month. Their survey of health care stakeholders found that 76 percent cite "reducing clinician burnout" as a major priority, and 85 percent say "recruiting/retaining nursing staff" is top of mind.
But only 45 percent of nurses responded "yes" when asked if generative AI can reduce clinician burnout.
I asked Dr. Peter Bonis, chief medical officer at Wolters Kluwer Health, to help me make sense of that gap—or "disconnect," as he called it.
"Our survey is indicating that there's an opportunity to work with allied health professionals and clinicians to deeply understand their needs and where some of these technologies can help; to have them on participatory boards as they themselves get educated on what these tools can do; and to select these tools so that they are optimizing their workflows, and they have agency in this process," he said.
I've been reporting on a lot of AI-related "disconnects" lately, both within health systems' AI deployment efforts and in external communications with vendors. I asked Bonis: Do these lapses indicate that we're taking the wrong approach to AI deployment in the health care industry?
He told me that this isn't exclusive to the health care industry, and that every business is wrestling with the same sort of issues. (Phew.) But, he acknowledged, health care is a high-stakes game, and it's important to deploy AI safely (and transparently) for the benefit of employees, patient care and overall health equity.
He believes health systems will succeed if they focus on patient care and bolster that foundation with sound operations and a successful business model.
"The fusion of those two directives is what creates a future-ready health care system that understands how to use these advanced technologies to advance their operations—to do that thoughtfully—and then to have a coherent pathway to start to use these tools to advance that higher stakes domain," Bonis said, "and that's the journey that we're on."
I also spoke with Dr. Perlin, head of the Joint Commission, about that journey to a "coherent" AI pathway. Read on to the Pulse Check section to see what he said.
Essential Reading
Aiming to improve the prior authorization process, HHS Secretary Robert F. Kennedy, Jr., and CMS Administrator Dr. Mehmet Oz hosted a roundtable of health insurance executives and stakeholders on Monday.
on Monday. Attendees agreed to six reforms: (1) standardizing electronic prior auth submissions, (2) reducing the volume of services that require prior auth, (3) honoring existing approvals during insurance transitions, (4) improving transparency and communication around decisions, (5) implementing real-time approvals for most requests by 2027 and (6) ensuring medical professionals review all denials.
(1) standardizing electronic prior auth submissions, (2) reducing the volume of services that require prior auth, (3) honoring existing approvals during insurance transitions, (4) improving transparency and communication around decisions, (5) implementing real-time approvals for most requests by 2027 and (6) ensuring medical professionals review all denials.
These companies were included in the discussion: Aetna, AHIP, Blue Cross Blue Shield Association, CareFirst BlueCross BlueShield, Centene Corporation, The Cigna Group, Elevance Health, GuideWell, Highmark Health, Humana, Kaiser Permanente and UnitedHealthcare. Together, they represent about 75 percent of Americans with commercial or Medicare Advantage plans.
The Lown Institute has released its highly anticipated index of America's Most Socially Responsible Hospitals. This year's honor roll comes at a critical time, as hospitals work to maintain equitable care amid potential Medicaid cuts, rising costs and ongoing workforce challenges. Duke Regional Hospital topped this year's acute care ranking, marking its fifth year on the list.
Eli Lilly's once-weekly insulin efsitora displayed promising results in Phase 3 clinical trials, reducing A1C and meeting safety standards for adults with Type 2 diabetes, according to detailed datapublished by the company this week. The new drug hopes to simplify diabetes management by reducing the frequency of insulin injections. Diabetes is becoming more prevalent in the United States , affecting nearly 15 percent of adults. By the end of 2025, Eli Lilly plans to submit the drug to global regulatory agencies for the treatment of Type 2 diabetes.
reducing A1C and meeting safety standards for adults with Type 2 diabetes, according to detailed datapublished by the company this week. The new drug hopes to simplify diabetes management by reducing the frequency of insulin injections.
Artisight, the NVIDIA-backed health tech company specializing in AI-powered "smart hospital" infrastructure, announced a $40 million investment from a dozen health systems. It's an unprecedented level of support from some of the nation's largest, most forefront integrated systems and academic medical centers. (The list of names was reviewed by Newsweek but is not being released to the public at this time.)
Pulse Check
Dr. Jonathan Perlin is president and CEO of the Joint Commission.
Dr. Jonathan Perlin is president and CEO of the Joint Commission.
Joint Commission
If you've been paying attention to the news lately, you may have had the same question that I did: What on earth is going on at the Joint Commission?The independent health care accreditation and certification organization has launched a couple high-profile, high-tech partnerships in recent weeks. First, it announced a long-term relationship with Palantir, intending to use the company's AI platform to streamline accreditation/certification processes. Then, it joined forces with the Coalition for Health AI to establish a "suite" of AI best practices playbooks and a new certification for hospitals. Now, if you work at a hospital, you likely live by the Joint Commission's standards. That's why I called Dr. Jonathan Perlin, president and CEO of The Joint Commission, last Friday. There was a bit of "geeking out about AI," as Perlin put it. But mostly, we discussed the recent CHAI partnership—and what it could mean for quality/safety standards and hospital certifications. Editor's Note: Responses are lightly edited for length and clarity.
AI is so different from other components used to assess quality. Each health system uses it in a unique way, and applications vary between hospitals, departments and even patient populations. "Good AI" can be tough to quantify. How do you plan to create a standard with this new certification program? CHAI's lane is really the technology itself, and ours is the organization's governance process for the responsible use of that. You may have seen our Responsible Use of Health Data Certification that has six attributes, and this is really an extension of that. What we anticipate—and this is a work in progress—is that building from the Responsible Use of Health Data [Certification], there'd be requirements for de-identification or privacy that could be data controls for security. There should be some mechanism for transparency with patients. Most importantly, there would be like an oversight or governance structure that addresses the algorithm's or the AI's performance. The notion is that an organization can look to CHAI and to the market to identify an AI tool, but it has to have an active and ongoing governance process to look at the performance of that tool in their environment. To give an example, I think there are three essential components. One is technical: Is [the tool] valid and reliable in a sort of mathematical sense? Second, is it valid and reliable clinically? Does it present the right clinical information? And third, is it valid and reliable in a demographic sense, that you're not applying an AI trained specifically for detection of sepsis in adults to children. To make that clear, if CHAI's lane is really the external performance of the algorithm and the assurance aspects outside of health care, the way we do this [new certification] is not specifically directed at the certification of the AI tool, but the certification of process for the organization's own governance and oversight of the use responsible use of that AI tool.
Will this certification assess tools that health systems developed internally, vendor tools that they deploy, or a combination of both? What else will you be looking at within each hospital's AI ecosystem? We anticipate that the certification, which would be given to health care organizations, would be based on the governance structure and the oversight structure I described [above]. We expect it would be applied both to homegrown and off-the-shelf technologies. Our focus is on continuous governance. Let me give an example that's literally closer to home. We just finished a renovation [at my house], and we had an electrical inspection after the work was completed. The wiring of the house is not going to change over time, but the wiring of AI, if it's retrained, if it drifts, etc., may change over time—so the organization needs to have a mechanism for periodic review of the performance of its "electrical system," to use the analogy, not just at inception, but periodically, or frankly, for the life of the use of that technology.
Any advice for health systems that are currently building up their AI governance structures, to ensure they're on the right path ahead of the Joint Commission and CHAI's certification?
Take a look at our Responsible Use of Health Data Certification , because it really provides insight into the concepts of governance as the regulatory frameworks are emerging. Despite the fact that device drug approvals are static, they are viewing the use of device (good outcomes or bad) as the responsibility of the clinicians and health care organizations that use those. Having come from operations and large systems myself, it's really important to have a set of externally validated standards that demonstrate what "good" looks like for responsible governance and oversight. I think organizations like ours are hugely excited about the potential, but we want to set up common standards to assure that we realize that potential responsibly.
If you liked this sneak peek, remember to check out next week's edition, which will include more of my interview with Perlin.
C-Suite Shuffles
Joseph Impicciche is retiring as CEO of Ascension, after six years at the helm of the St. Louis-based system. Eduardo Conrado, the health system's current president, will become its new CEO on January 1, 2026. Conrado was named to Ascension's executive team in 2018, after five years on its board of directors. Throughout his tenure, he has also served as the system's chief digital officer and chief strategy and innovation officer.
The Medical University of South Carolina (MUSC) has selected Dr. John Marymont as its next provost and executive vice president for academic affairs. Currently, he serves as vice president for medical affairs and dean of the medical college at the University of South Alabama.
Lovelace Health System is undergoing its fourth CEO change since 2022, the Albuquerque Journal reported. President and CEO Troy Greer resigned last week after two years in the role. The health system—one of the largest in New Mexico—declined to comment on his exit.
Executive Edge
Dr. Leigh Vinocur is a thought leader on stress management amongst health care professionals.
Dr. Leigh Vinocur is a thought leader on stress management amongst health care professionals.
Dr. Leigh Vinocur
Dr. Leigh Vinocur tells me that she considers herself a "lifelong learner." She's spent her career learning different elements of medicine, starting as a urology resident, becoming a board-certified emergency physician and serving as chief medical director for a major health system, overseeing more than 100 providers in the mid-Atlantic region. Now, she is the medical director of a men's health clinic and works part-time in clinical trials at a nutraceutical company. But throughout her working life, Vinocur has also learned a great deal about stress. After leaving her big-box health care role, she dealt with a "corporate medicine hangover." On July 12, she's releasing a book about her journey: Never Let Them See You Sweat: How Science Can Help Us Harness Stress for Success. This week, I connected with Vinocur to learn what her research—and personal experiences—taught her about stress in the health care setting. Here's what she told me: Editor's Note: Responses are lightly edited for length and clarity. "Today, in this political climate, we're seeing changes to health care, erosion of public health. It's making it even more difficult [to work in health care leadership]. There were always issues as a physician, fighting with insurance companies—but as physician executives, it's that kind of double bind that they're in, because they're caregivers, but they're administrators. They have rules they're enforcing, fiscal and institutional constraints, but they have to put their patients first, too. And it's stressful.
"Not all stress is always horrible and bad. It gets you to your tiptop performance, you know. Stress was an evolutionary development and advantage to keep us safe. If you were out there being chased by a predator, all those reactions from the hypothalamus, the pituitary, the adrenal release the cascade of hormones for that fight or flight. Whether you're a runner in the Olympics standing in the blocks, or whether you're an ER doctor waiting in the resuscitation room for those accident victims to come in, that little boost of stress gets you at your top performance. It's just this continued stress that is so challenging.
"I tell executive leaders that they need some buffer in between meetings. You need to create little micro-breaks during the day that are just for you to calm down. Whether that's meditation (there are apps on our watches and our phones), deep breathing (like box breathing, where you inhale through your nose for four seconds, hold it for four seconds and exhale for four seconds through your mouth), or leadership mentoring (where you have open dialogue and create a safe space to talk about some of the ethical dilemmas you may be facing).
Whether that's meditation (there are apps on our watches and our phones), deep breathing (like box breathing, where you inhale through your nose for four seconds, hold it for four seconds and exhale for four seconds through your mouth), or leadership mentoring (where you have open dialogue and create a safe space to talk about some of the ethical dilemmas you may be facing). "All throughout the book, there are discussions on things you can do in nature, like 'forest bathing.' Study after study says that if you can get to a green space, like a park, that can lower your blood pressure. Just being out in nature, getting outside—you don't even have to exercise—can be a great relief."
This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ozempic Linked to Reduced Cancer Risk
Ozempic Linked to Reduced Cancer Risk

Newsweek

timea minute ago

  • Newsweek

Ozempic Linked to Reduced Cancer Risk

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer compared to those with obesity who do not. Looking at 14 cancers, of which 13 were associated with obesity, scientists discovered people taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)—the official name for the class of drugs—had a small reduction in risk of any of the cancers. The risk was most strongly reduced for endometrial, meningioma and ovarian cancers, according to the study. However, the researcher's analysis also revealed there was some evidence of an increased risk of kidney cancer among the GLP-1RA group. Hands in blue surgical gloves holding Ozempic injection pen. Hands in blue surgical gloves holding Ozempic injection than 2 in 5 adults (42.4 percent) are considered obese in the U.S., while nearly 1 in 3 adults (30.7 percent) are overweight. GLP-1RAs, meanwhile, have soared in popularity as a promising intervention for obesity amid the rising burden of the chronic disease, its associated illnesses and healthcare costs. While many of these medications contain the same ingredient under a different brand name, the drugs are licensed in different ways. In the U.S. Ozempic, for example, is approved for use in people with type 2 diabetes, while Wegovy is approved for those with obesity or who are overweight and have related health problems. While some research has suggested cardiovascular benefits of GLP-1RAs, for example, other studies have indicated an increased risk of pancreatitis. "This study is among the first to examine the association between GLP-1 receptor agonist (GLP-1RA) use and cancer risk in a broad real-world population of overweight and obese adults, regardless of type 2 diabetes status. Previous studies mainly focused on patients with type 2 diabetes," study authors Jiang Bian of Indiana University Dr. Serena Jingchuan Guo of University of Florida told Newsweek. In their work, the team matched more than 40,000 adults with obesity or who were overweight using GLP-1RAs with more than 40,000 non-users with obesity or who were overweight—and monitored both groups for cancer diagnoses over 10 years. Participants came from the OneFlorida+ Clinical Research Network, which spans 14 healthcare organizations and 20 million individuals across Alabama, Florida and Georgia. The incidence rate of "overall" cancers was 20.5 per 1,000 person-years for GLP-1RA users, compared to 23.6 per 1,000 person-years for non-users, Bian and Jingchuan explained. There was about a 17 percent relative reduction in overall cancer risk. For those using GLP-1RAs, there was about a 25 percent risk reduction of endometrial cancer, about a 47 percent risk reduction of ovarian cancer and around a 31 percent risk reduction of meningioma. Pink and purple 3D illustration representing endometriosis cancer. Pink and purple 3D illustration representing endometriosis study also suggested there was a 38 percent increased risk of kidney cancer, though the result was only "borderline significant" according to Bian and Dr. Jingchuan. The risk was particularly higher in younger patients below the age of 65. The 13 obesity-associated cancers looked at included bladder, breast, colorectal, endometrial, kidney, liver, meningioma, multiple myeloma, ovarian, pancreatic, prostate, thyroid and upper gastrointestinal. The team also looked at lung cancer. Bian and Jingchuan explained that there are three ways these findings could be used to help patients with obesity and prevent certain types of cancer. Risk–benefit assessment: GLP-1RAs may be considered not only for weight loss and cardiometabolic benefits but also for cancer prevention in high-risk obese patients, particularly for endometrial and ovarian cancers. Personalized medicine: tailoring GLP-1RA prescriptions based on patient profile (e.g. age, BMI and comorbidities). Monitoring: Clinicians should remain cautious about potential kidney cancer risk and consider targeted screening in at-risk groups. "This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including lower risks of endometrial, ovarian, and meningioma cancers, among patients with obesity or overweight," the team explained in their paper. "However, taking GLP-1RAs may be associated with an increased risk of kidney cancer, highlighting the need for longer-term follow-up to clarify the underlying mechanisms and clinical implications of these findings." As well as larger, long-term studies to confirm the cancer-protective effects, especially for rarer cancers, further research will include mechanistic studies clarifying biological pathways (weight loss vs. drug effects vs. glycemic control) and identifying patient subgroups (via machine learning) most likely to benefit—or be harmed—by GLP-1RA therapy. GLP-1RAs are most effective for long-term obesity treatment and management when delivered alongside behavior and lifestyle support. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1RA drugs? Let us know via health@ Reference Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J., Guo, Y., Sun, R. C., Guo, J., & Bian, J. (2025). GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncology.

America is Aging—and It's Not Ready, Researchers Warn
America is Aging—and It's Not Ready, Researchers Warn

Newsweek

timea minute ago

  • Newsweek

America is Aging—and It's Not Ready, Researchers Warn

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As the population of the United States grows older, a new study warns that the country lacks the infrastructure and policy direction to meet the needs of its aging citizens. The research by Northeastern University analyzes access to essential services for older adults across the U.S. Researchers found that while some communities offer decent access, others face stark deficiencies—in some states like Arizona, up to 70% of high-aging communities lack sufficient services tailored to seniors. "We predict that without a significant policy shift, many of the demands for the aging population in the society will not be met," Ryan Wang, associate professor and vice chair for research of civil and environmental engineering at Northeastern, said in a press release. Stock image: Young and senior people holding hands. Stock image: Young and senior people holding hands. Photo by Eda Hoyman / Getty Images In an email, Wang told Newsweek said the inspiration for the research "really hits close to home" for the professor. "I would watch my own older relatives, my grandparents and now my parents, navigate their daily lives, and I saw firsthand how a simple trip to the doctor or the grocery store could become a major logistical challenge," Wang said. "It made me realize that it's not just about whether a service exists nearby, but about the real-world, often invisible, barriers to getting there: the distance, the safety of the walk, the transportation options. "I saw how these small, daily hurdles could chip away at their independence and well-being." Why It Matters The country's demographic transformation is not a distant concern. As early as 2040, more than 20% of Americans will be 65 or older, according to federal projections. Without proactive urban planning and expanded services, seniors will face growing challenges accessing daily essentials, according to Northeastern's findings. The problem is not uniform—some states like Florida, with established aging policies, perform better. "Florida demonstrates a consistently stronger and more positive association between its ageing population and access to essential services," Wang told Newsweek. "I think this can be attributed to Florida's long-standing infrastructure and policy efforts targeted at older populations (they of course have a growing population of seniors) may be having a positive effect." However, some states—including California and Arizona—reveal inconsistent service access, even among similar high-aging populations. In Arizona alone, 70% of high-aging communities were found to lack aging-specific services like nursing care or home health support, according to Wang. "Another challenge is that many current policies are reactive rather than proactive," Wang told Newsweek. "Our projections show that the accessibility advantages some high-ageing communities currently enjoy are likely to decline by 2030 and 2060 as the elderly population grows. "This indicates a potential for widening disparities if we don't plan for the future. Without forward-looking policies that anticipate demographic shifts, we risk falling behind and failing to meet the increasing demand for services." What to Know While the study surprisingly found no significant disparities in national-level service accessibility between older and younger communities, localized gaps are pronounced. Wang said that city design will play a central role in any solution, citing the "15-minute city" model—where daily needs are reachable within a 15-minute walk or ride—as one approach. What People Are Saying "At this stage, we are not ready for the aging population," Wang said in the release. "Population aging is not a critical social issue at this point in the U.S. compared to some other countries—Korea, Japan some European countries—but that does not mean that it will stay like this. "We predict that without a significant policy shift, many of the demands for the aging population in the society will not be met." What's Next As the population continues to age, service deserts could become more widespread unless addressed through policy and planning. "It is important to know: 'Longevity-ready cities aren't about helping the elderly—they are about ensuring every one of us can move, thrive and survive," Wang told Newsweek. "Policies that improve walkability, access to health care and community services create a more livable and equitable environment for people of all ages. Everyone needs mobility to maintain their physical, mental and neurological health."

I Tested Out the $349 Headband That Trains Your Brain for Better Sleep, and It Actually Works
I Tested Out the $349 Headband That Trains Your Brain for Better Sleep, and It Actually Works

CNET

time30 minutes ago

  • CNET

I Tested Out the $349 Headband That Trains Your Brain for Better Sleep, and It Actually Works

Cole Kan/CNET I love naps, particularly power naps. Power naps are the perfect way to get that much-needed rest to help you get through the rest of your day. So when I had the chance to take a nap for work purposes, it immediately caught my attention. The assignment was to test a headband that promises to help you sleep on demand, and I was excited to give it a go. This Elemind headband is sleek and comfortable. Coming in at $349 (and an optional subscription fee if you need to access your sleep data), it's not exactly cheap. But it does come loaded with tech, including EEG functionality to read your brainwaves, an AI for processing that brain activity, and audio output to produce sounds that induce sleep -- a low-pitch, rhythmic buzz you can also feel. The sensation isn't intrusive or distracting, but rather almost feels like a light massage. "It's basically noise-canceling those brain waves that keep you awake," Meredith Perry, co-founder of Elemind, tells me. There are plenty of Reddit threads because of the intrigue around this device. The discussion is around whether it actually works, with many folks recommending it, while some others being on the fence about this tech, stating that it may be too early to be a market-ready device. To find the answers, I set out to test it myself. I've been working in the sleep industry for years and I've seen and tested a variety of gadgets and products that claim to help you sleep better. Honestly, I understand the skepticism surrounding a product like this, because not many such devices live up to their promises. Naturally, I was very eager to see if the Elemind headband was among the hundreds that didn't work or if it was going to be the breakthrough the space needed. Here's what I found. Putting the Elemind to the test Nasha Addarich Martinez/CNET I arrived at The Crosby Street Hotel in New York for my nap. Perry greeted me at the entrance of the room and explained the technology behind Elemind and to showed me how to properly put on the headband and turn it on. She also showed me how the app works and the data I can access when wearing the headband. Then she left me to nap. I'll briefly describe what happened next because -- spoiler -- I fell asleep. I remember lying down and hearing a low buzz that resembled bone conduction. I could hear the buzzing, but I could also feel it. At first, the rhythm was fast-paced, but as I started to drift off I felt it getting slower. The next thing I knew, I was waking up to the sound of the room door opening. It was Perry with a big smile because she knew the headband had worked based on my half-opened eyes and the bewildered look on my face. The nap was pretty short. We set the headband to 25 minutes. This wasn't my typical nap. Instead of a deep sleep, I felt like I was in an alpha state -- like a light sleep where I was still aware of my surroundings. When I woke up, I felt exactly how I normally feel after a nap, which was a little groggy. That feeling lasted only a few minutes, and I continued my day with no side effects or grogginess. This is the first sleep tech device I've seen that targets brain waves and redirects them in real-time. Research affiliated with Elemind claims that 76% of the people who wore the headband fell asleep faster, and that was certainly the case for me. What the data says According to the data I received from my nap, which was reviewed by neuroscientists at Elemind, my alpha wave activity remained high during my nap, which indicates that while I was resting and in light sleep, I didn't go into a deep sleeping stage. I suspected that would be the case for a 25-minute nap, and that also aligns with my experience wearing the headband. (I was aware of my surroundings but in a light sleep, kind of like how you feel when you're about to wake up in the morning.) Elemind The image above, which Elemind refers to as a plot, is a polar histogram that shows the performance of the headband while tracking my alpha waves. On the left side, the plot shows the target onset phase and the distribution of all the stimuli (gray bars). The right side is a similar plot but for the target stimulus offset phase. More simply put, "the onset [is] the phase of the brainwave when each sound pulse starts and offset is the phase of the brainwave when each sound pulse ends," said Ryan Neely, VP of science and research at Elemind. All of this means that the headband was working as intended (more pulses at the beginning when my brainwave activity was high, then, less frequently when my target brainwave activity was reached (224 degrees). The data confirms what I felt during my nap -- that I had a light sleep nap. I certainly felt like I was resting and also felt I fell asleep pretty fast (what I felt was only about a few minutes). I'd say it was a pretty good power nap, especially since it was only 25 minutes long at 2 p.m. I'm curious to see if it'll induce me into a more deep sleep during the night when I'm in the comfort of my home. How does the Elemind work? The headband is designed to help users fall asleep by targeting their alpha wave activity with sound pulses. This is a core feature of the patented algorithm that was developed at MIT and built into each band. Perry explained that the headband uses noninvasive neuromodulation technology to track your EEG brain activity and deliver acoustic stimulation synced to your brain's natural rhythms, in actual time. Every night you wear the headband, it learns more and evolves with you through its AI capabilities, becoming more effective with time. The AI behind the headband, which Elemind refers to as Sleep Tailor, learns your unique brain activity and sleep patterns to improve your rest. It gathers your sleep data and analyzes it to generate stimulation patterns to offset your brain activity. The headband can be worn all night and is comfortable enough to wear in all sleeping positions. Users can use Elemind in any way that suits their needs. For example, you can wear the headband just to fall asleep and take it off during the night, or you can choose to put the headband on only if you wake up and need help falling back to sleep. You can also use Elemind to nap during the day. To experience all of the Elemind's features, it's recommended that you wear it all night. You'll be able to use it to help you fall asleep, with real-time sleep staging, which will result in a comprehensive sleep report post-session, and to fall back asleep faster if you wake up up earlier than intended. Soon, the Elemind will also have a deep sleep stimulation feature, which will amplify delta waves during slow-wave sleep. Is the Elemind comfortable? I found the Elemind headband to be comfortable. It's made of soft material and it's adjustable in the back so you can make it tighter or looser as you prefer it. It should be tight enough that it doesn't fall off, but not tight enough that it's uncomfortable to sleep with. I mostly napped on my back, so I didn't have any issues with it sliding off. I did briefly lay on my side and couldn't feel it shifting or bunching up. For accurate readings, you only need to ensure that the sensors are in contact with your forehead. If you have long hair, Perry recommends wrapping it around your neck and under the hair, then gently sliding it up to your forehead and behind your ears. Lai Umali/CNET Is the Elemind worth it? Whether the Elemind headband would be worth the $349 to you will depend on a few factors. You might like Elemind if: You travel often and struggle with jetlag. You find it difficult to fall sleep. You wake up frequently during the night and struggle to fall back asleep. Elemind might not be for you if: You find a subtle buzz on your forehead too distracting. You don't have issues falling asleep or staying asleep. Where can I buy the Elemind headband? You can order the Elemind on its website. The product is past the preorder stage and is now available for purchase. In addition to the $349 price for the device, there's an optional membership to access sleep tracking, scores and metrics. Without the membership, you can still access the headband's core features of falling asleep and falling back to sleep faster. You do get the first month free with the purchase of the headband. You can choose to pay the membership annually, which will run you about $7 a month, or to pay it in monthly installments of $13.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store